BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34620729)

  • 1.
    Mahajan S; Barker CA; Mauguen A; D'Angelo SP; Yeh R; Pandit-Taskar N
    J Nucl Med; 2022 Jun; 63(6):906-911. PubMed ID: 34620729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma.
    Byrne K; Siva S; Chait L; Callahan J; Bressel M; Seel M; MacManus MP; Hicks RJ
    J Nucl Med; 2015 Sep; 56(9):1328-33. PubMed ID: 26159592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia.
    Concannon R; Larcos GS; Veness M
    J Am Acad Dermatol; 2010 Jan; 62(1):76-84. PubMed ID: 20082888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of clinical impact of
    Liu J; Larcos G; Howle J; Veness M
    Australas J Dermatol; 2017 May; 58(2):99-105. PubMed ID: 26459330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Impact of FDG PET/CT of the Lower Extremities in Patients With Merkel Cell Carcinoma With Primary Disease Site Outside of the Lower Extremities.
    Ishiyama M; Behnia F; Vesselle H
    AJR Am J Roentgenol; 2021 Mar; 216(3):776-780. PubMed ID: 33474987
    [No Abstract]   [Full Text] [Related]  

  • 7. The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution.
    George A; Girault S; Testard A; Delva R; Soulié P; Couturier OF; Morel O
    Nucl Med Commun; 2014 Mar; 35(3):282-90. PubMed ID: 24240193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinoma.
    Zijlker LP; Bakker M; van der Hiel B; Bruining A; Klop WMC; Zuur CL; Wouters MWJM; van Akkooi ACJ
    J Surg Oncol; 2023 Apr; 127(5):841-847. PubMed ID: 36573839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic assessment of Merkel cell carcinoma: the role of 18F-FDG PET/CT.
    Ben-Haim S; Garkaby J; Primashvili N; Goshen E; Shapira R; Davidson T; Israel O; Epelbaum R
    Nucl Med Commun; 2016 Aug; 37(8):865-73. PubMed ID: 27092665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET provides high-impact and powerful prognostic stratification in the staging of Merkel cell carcinoma: a 15-year institutional experience.
    Siva S; Byrne K; Seel M; Bressel M; Jacobs D; Callahan J; Laing J; Macmanus MP; Hicks RJ
    J Nucl Med; 2013 Aug; 54(8):1223-9. PubMed ID: 23753187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Test Accuracy of 18 F-FDG PET or PET/CT in Merkel Cell Carcinoma.
    Shim SR; Kim SJ
    Clin Nucl Med; 2022 Oct; 47(10):843-848. PubMed ID: 35777979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restaging [
    Mahajan S; Barker CA; Mauguen A; Singh B; Pandit-Taskar N
    J Am Acad Dermatol; 2020 Apr; 82(4):878-886. PubMed ID: 31562942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of whole-body
    Ozturk K; Gencturk M; Caicedo-Granados E; Li F; Cayci Z
    Eur Arch Otorhinolaryngol; 2019 Mar; 276(3):847-855. PubMed ID: 30604061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Merkel cell carcinoma: Is there a role for 2-deoxy-2-[f-18]fluoro-D-glucose-positron emission tomography/computed tomography?
    Iagaru A; Quon A; McDougall IR; Gambhir SS
    Mol Imaging Biol; 2006; 8(4):212-7. PubMed ID: 16724293
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kim SA; Roh JL; Kim JS; Lee JH; Lee SH; Choi SH; Nam SY; Kim SY
    Eur J Cancer; 2017 Feb; 72():62-70. PubMed ID: 28027517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center.
    Hawryluk EB; O'Regan KN; Sheehy N; Guo Y; Dorosario A; Sakellis CG; Jacene HA; Wang LC
    J Am Acad Dermatol; 2013 Apr; 68(4):592-599. PubMed ID: 23127473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis.
    Park S; Lee HY; Lee S
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):215-224. PubMed ID: 34106327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-fluorodeoxyglucose positron emission tomography-computed tomography imaging in the management of Merkel cell carcinoma: a single-institution retrospective study.
    Ibrahim SF; Ahronowitz I; McCalmont TH; Hernandez Pampaloni M; Ryan JL; Yu SS
    Dermatol Surg; 2013 Sep; 39(9):1323-33. PubMed ID: 23777452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.